Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Minneapolis, Minnesota

This page shows live ClinicalTrials.gov search results for Minneapolis, Minnesota, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
7864
Shown on this page
12
Current sort
Recently updated
Location scope
Minneapolis, MN
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Minneapolis, Minnesota. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 337–348 of 7,864 matching trials in Minneapolis, MN.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 2

NCT07875790
View directory record Official record
Conditions
SCHIZOPHRENIA 1 (Disorder), Schizo Affective Disorder, Healthy Adult
Interventions
Motion Perception Task, Sine Wave Speech Task, Volatility Task, Choice Probabilistic Reversal Task, Kamin Blocking Task, Minnesota Trust Game, Dynamic Trust Game
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 59 Years
Enrollment
325 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2028 – 2031
U.S. locations
5
States / cities
Irvine, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 5, 2026, 4:23 AM EST
Recruiting Phase 3 Interventional

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

NCT05946213
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, External Beam Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Procedure · Radiation · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2041
U.S. locations
424
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Little Rock, Arkansas + 318 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 5, 2026, 4:23 AM EST
Recruiting Phase 2 Interventional

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

NCT05408845
View directory record Official record
Conditions
Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Unresectable Salivary Gland Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Docetaxel, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Questionnaire Administration, Trastuzumab, Trastuzumab Deruxtecan, Trastuzumab Emtansine
Procedure · Drug · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
154
States / cities
Birmingham, Alabama • Duarte, California • Dublin, California + 127 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 5, 2026, 4:23 AM EST
Recruiting Phase 1 Interventional

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

NCT07012044
View directory record Official record
Conditions
Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine, Decitabine and Cedazuridine, Filgrastim, Imaging Procedure, Lumbar Puncture
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 5, 2026, 4:23 AM EST
Recruiting Phase 3 Interventional

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

NCT07097142
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Biospecimen Collection, Cisplatin, Computed Tomography, Fluorouracil, Gemcitabine, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Mitomycin, Positron Emission Tomography, Survey Administration, Ultrahypofractionated Radiation Therapy
Procedure · Drug · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
258
States / cities
Fairbanks, Alaska • Fort Smith, Arkansas • Little Rock, Arkansas + 196 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 5, 2026, 4:23 AM EST
Not yet recruiting Phase 2 Interventional

Mitigating DKA in Type 1 Diabetes for Safe Use of SGLT Inhibitors Using Dual Continuous Ketone and Glucose Monitoring.

NCT07325201
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), Chronic Kidney Disease, Diabetic Ketoacidosis, Ketones
Interventions
Sotagliflozin initiation
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 5, 2026, 4:23 AM EST
Recruiting Not applicable Interventional

R01_Pilot Jaw Muscle Phenotypes

NCT07153107
View directory record Official record
Conditions
Chronic TMD Pain, Temporomandibular Disorder
Interventions
Local Heat Therapy
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 5, 2026, 4:23 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment

NCT05489614
View directory record Official record
Conditions
Renal Impairment
Interventions
Olpasiran
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
6
States / cities
Rialto, California • Yucaipa, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 5, 2026, 4:23 AM EST
Active, not recruiting Not applicable Interventional

tDCS With Cognitive Training to Reduce Impulsivity and Weight in Veterans With Obesity

NCT05225233
View directory record Official record
Conditions
Obesity
Interventions
Sham Transcranial Direct Current Stimulation (tDCS), Active Transcranial Direct Current Stimulation (tDCS)
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 5, 2026, 4:23 AM EST
Recruiting Not applicable Interventional

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

NCT03723928
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Interventions
Usual care disease monitoring, Serum Tumor Marker directed disease monitoring, Quality-of-Life Assessment, Anxiety Questionnaire Administration
Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
709
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 456 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 5, 2026, 4:23 AM EST
Active, not recruiting Not applicable Interventional

International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry

NCT01464606
View directory record Official record
Conditions
Pleuropulmonary Blastoma
Interventions
Vincristine, Dactinomycin, Cyclophosphamide, Ifosfamide, Doxorubicin
Drug
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
Up to 21 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2035
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 5, 2026, 4:23 AM EST
Recruiting Not applicable Interventional

Adjunctive Motivational Alcohol Intervention to Prevent IPV

NCT05287711
View directory record Official record
Conditions
Alcohol Use and Intimate Partner Violence
Interventions
Motivational Enhancement Therapy, Alcohol Education Control, Treatment as Usual, Strength at Home
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 5, 2026, 4:23 AM EST